Skip to main content
Terug
Watch Compare

Can-Fite BioPharma Ltd.

Datakwaliteit: 100%
CANF
NYSE Manufacturing Chemicals
€ 2,92
▼ € 0,01 (-0,34%)
Marktkapitalisatie: 6,85 M
Prijs
€ 2,92
Marktkapitalisatie
6,85 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -16,99% annually over 5 years
Negative free cash flow of -8,95 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 22,92%
Capital efficient — spends only 0,49% of revenue on capex

Groei

Revenue Growth (5Y)
-16,99%
Onder sectorgemiddelde (1,92%)
Revenue (1Y)-39,91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-295,00%
Onder sectorgemiddelde (-54,44%)
ROIC-164,88%
Net Margin-2426,67%
Op. Margin-2456,79%

Veiligheid

Debt / Equity
N/A
Current Ratio3,60
Interest Coverage-35,04

Waardering

PE (TTM)
-0,70
Boven sectorgemiddelde (-1,49)
P/B Ratio1,64
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,7 -1,5
P/B 1,6 1,6
ROE % -295,0 -54,4
Net Margin % -2426,7 -41,5
Rev Growth 5Y % -17,0 1,9
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 2,92
+1612.3%
Koersdoel
€ 50,00
€ 50,00
€ 50,00
€ 50,00
Vooruitzicht
Forward WPA -€ 1,04
Omzet Sch. 1,41 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,04
-€ 1,04 – -€ 1,04
 1,41 M 1
FY2026 -€ 1,97
-€ 1,97 – -€ 1,97
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 2,80 N/A —
Q32025 -€ 2,80 N/A —
Q22025 -€ 2,40 € 0,00 +100,0%
Q12025 -€ 2,40 N/A —

ETFs Holding This Stock

AVEE logo AVEE Avantis Emerging Markets Small Cap Equity ETF
0,05% weight
AVES logo AVES Avantis Emerging Markets Value ETF
0,04% weight
IND logo IND Xtrackers Nifty 500 India ETF
0,04% weight
AVSE logo AVSE Avantis Responsible Emerging Markets Equity ETF
0,03% weight
AVXC logo AVXC Avantis Emerging Markets ex-China Equity ETF
0,02% weight
WLCTX WLCTX
0,01% weight
WLTTX WLTTX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -39,91% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -16,99% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 405.000,0 Net Income (TTM) -9,83 M
ROE -295,00% ROA -144,08%
Gross Margin N/A Operating Margin -2456,79%
Net Margin -2426,67% Free Cash Flow (TTM) -8,95 M
ROIC -164,88% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,60
Interest Coverage -35,04 Asset Turnover 0,06
Working Capital 5,50 M Tangible Book Value 4,18 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,70 Forward P/E N/A
P/B Ratio 1,64 P/S Ratio 16,92
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 4,87 Fwd Earnings Yield N/A
FCF Yield -130,63%
Market Cap 6,85 M Enterprise Value 398.233,0
Per Share
EPS (Diluted TTM) -5,97 Revenue / Share 0,17
FCF / Share -3,81 OCF / Share -3,81
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,49% FCF Conversion 91,08%
SBC-Adj. FCF -9,63 M Growth Momentum -22,92

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 405.000,0 674.000,0 — 810.000,0 853.000,0
Net Income -9,83 M -7,88 M -7,63 M -10,17 M -12,62 M
EPS (Diluted) -5,97 0,00 -0,01 -0,01 —
Gross Profit — — — — —
Operating Income -9,95 M -8,13 M -8,20 M -10,10 M -12,84 M
EBITDA — — — — —
R&D Expenses 6,69 M 5,76 M 5,98 M 7,76 M 9,85 M
SG&A Expenses — — — 263.000,0 —
D&A 24.000,0 — — 14.000,0 14.000,0
Interest Expense 284.000,0 -291.000,0 — -77.000,0 227.000,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9,51 M 9,12 M 9,99 M 9,28 M 20,25 M
Total Liabilities — — — — —
Shareholders' Equity 5,59 M 5,44 M 6,24 M 4,47 M 14,38 M
Total Debt — — — — —
Cash & Equivalents 5,53 M 4,83 M 4,28 M 2,98 M 4,39 M
Current Assets 9,44 M 8,98 M 9,91 M 9,16 M 20,07 M
Current Liabilities 2,73 M 2,05 M 2,02 M 2,50 M 2,73 M